Gastroenterology strain | Antipathogenic activity
Characteristics
FUNCTIONALITY
Inhibition of E. coli
Scientific support
In vitro studies
Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
Immunology blend | Immune stimulation
- Lactobacillus rhamnosus – LR04 (DSM 16605)
- Lactobacillus rhamnosus – LR05 (DSM 19739)
- Lactobacillus plantarum – LP01 (LMG P-21021)
- Lactobacillus plantarum – LP02 (LMG P-21020)
- Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 5 billion CFU + FOS or GOS
FUNCTIONALITY
Reinforcement of the natural defences • Reduction of the intestinal discomfort • Rebalance of the intestinal microbiota
Scientific support
Human clinical trial
1) Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233.
2) Belcaro G. et al. Prevention of flu episodes with colostrum and Bifivir compared with vaccination: an epidemiological, registry study. Panminerva Medica 2010;52:269-75.
In vitro study
Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Gastroenterol. 2018;52:S57-S61.
+ Internal data on immune stimulation and anti-pathogen activity available upon request for certain strains
Immunology blend | Immune stimulation
- Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)
- Lactobacillus rhamnosus – LR04 (DSM 16605)
- Lactobacillus plantarum – LP02 (LMG P-21020)
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
10 billion CFU + 10 billion CFU + 10 billion CFU + 3g
FUNCTIONALITY
Reinforcement of the natural defences • Reduction of the incidence, severity and duration of Acute Respiratory Infections (ARI) during the cold season
Scientific support
Human clinical trial
Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroente- rology, 2008; 42(2): 224-233.
In vitro study
Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Ga- stroenterol. 2018;52:S57-S61.
+ Internal data on immune stimulation and anti-pathogen activity available upon request for certain strains
Gynecology blend | Vaginal candidiasis – Bacterial vaginosis
- Lactobacillus plantarum – LP02 (LLMG P-21020)
- Lactobacillus fermentum – LF10 (DSM 19187)
Characteristics
DAILY DOSAGE IN CLINICAL STUDY
500 million per strain
FUNCTIONALITY
Vaginal health • Counteraction of Candida vulvovaginitis • Counteraction of Candida vulvovaginitis including recurrence
Scientific support
Clinical study
Murina F. et al. Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. New Microbiologica, 41,3, 220-224, 2018, ISN 1121-7138.
Urology strain | Antipathogenic activity
Characteristics
FUNCTIONALITY
Cystitis • Inhibition of E. coli
Scientific support
In vitro studies
Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
+ Internal data on anti-inflammatory and anti-oxidant properties available upon request for some of these strains
